Tyvaso FDA Approval History
FDA Approved: Yes (First approved July 30, 2009)
Brand name: Tyvaso
Generic name: treprostinil
Dosage form: Inhalation Solution
Company: United Therapeutics Corporation
Treatment for: Pulmonary Hypertension
Tyvaso (treprostinil) is an inhaled prostanoid analogue indicated for the treatment of pulmonary arterial hypertension.
Development Timeline for Tyvaso
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.